Effect of early initiation of evolocumab and Combination lipid-lowering agent (statin + ezetimibe) on lipid profiles changes in patients with acute coronary Syndrome undergoing percuTAneous coronaRy intervention: a prospective, randomized controlled trial (C-STAR trial)
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0007908
- Lead Sponsor
- Yonsei University Yongin Severance Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 102
(1) Over 19 years old
(2) Patients who agreed to the research protocol and clinical follow-up survey plan, decided to participate in this study voluntarily, and gave written consent to the informed consent form.
(3) Patients who underwent percutaneous coronary stenting for acute coronary syndrome
? Patients who have previously taken statins,
? Patients with active liver disease or patients with three times or more increase in AST or ALT
? If you have an allergic or hypersensitivity reaction to Evorucumab, statin, or Ezetimib,
? Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study
? The remaining life expectancy is expected to be less than a year.
? Subjects who visited the hospital due to psychogenic shock and are expected to be less likely to survive by medical judgment
? Subjects participating in a randomized clinical trial of medical devices/pharmaceuticals
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference in LDL level change after 2 weeks of discharge compared to baseline in test group and control group
- Secondary Outcome Measures
Name Time Method Percent change in LDL level;Presence or absence of side effects (muscle pain, digestive disturbance, test abnormalities);LFT, CK, HbA1c level